Plunkett Research Online: Immuron Limited

IMMURON LIMITED (IMRN:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Immuron Limited is a biopharmaceutical company in Australia. Its products target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver (NASH) and prevention of influenza. The firm currently has one product in the market and seven products under research and develo.....



Immuron Limited
Ticker: IMRN
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 61 386371107
Fax: 61 390184881
Address: 62 Lygon Street
Level 3
Carlton South
Melbourne, VIC 3053 Australia

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals
ContactsDescription
Roger AstonChairman of the Board/Director
Jerry KanellosChief Scientific Officer/COO/CFO
See More
Immuron Limited is a biopharmaceutical company in Australia. Its products target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver (NASH) and prevention of influenza. The firm currently has one product in the market and seven products under research and develo.....See More See More

Auditor: PricewaterhouseCoopers
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201720162015
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: